Patients with sepsis are often treated in areas of intensive care given that close monitoring and intense therapeutic support are needed [
17]. Early treatment includes the use of timely, appropriate antibiotics, intravenous fluids, oxygen therapy as well as vasopressor and inotropic support where needed. Other additional treatments including extracorporeal or so-called blood purification techniques (BPT) have also been tried [
18]. These techniques include (among others): haemofiltration, haemoperfusion, intermittent or continuous high-volume haemofiltration (HVHF), plasmapheresis or adsorption. The rationale behind such an approach is to achieve “immune homeostasis” which theoretically reduces the potential damage caused by dysregulation of the host response to infection. This may be heralded by a profound rise in inflammatory mediators including cytokines which contribute to the dramatic systemic effects of sepsis, mainly in septic shock [
9,
19]. The recently updated Sepsis 3.0 consensus definitions state that sepsis is an infection accompanied by life-threatening organ dysfunction caused by a dysregulated host response [
20]. Given the pivotal role of cytokine production in sepsis, it follows that removal of these substances, through such BPT, may attenuate the response particularly in the early phase of sepsis [
21]. Several hypotheses have been proposed as to the potential mechanisms underpinning potential benefit. These include cytotoxic theories including the
peak concentration hypothesis whereby all inflammatory mediators are removed at a given rate, dependent on the BPT used and assuming they are filtered [
21‐
24]. Alternatively, the
cytokinetic theory proposes that cytokines are removed, thereby creating a cytokine gradient between the bloodstream and tissues allowing leucocyte-enhanced trafficking [
25]. In the same line, cytokine levels can also be seen as communicating messengers to talk to cells, recruit some, depress others and reduce cell metabolism for others [
22]. Despite early promise, no multicentre randomized controlled studies have demonstrated a survival benefit including the use of HVHF where higher flows may lead to increased cytokine removal were tried (
the cytotoxic threshold immune modulation hypothesis) [
26‐
28]. Other extracorporeal blood purification therapies also have failed with significant outcome data lacking with no treatment demonstrating a translatable survival benefit in any randomized controlled study [
29‐
31]. This somewhat too simplistic view takes into account several new concepts. Indeed, blood level of mediators (more than cytokines) implies the saturation of the interstitial and cellular compartments to be present in the blood. It is the so-called
tip of the iceberg theory [
31]. This theory is very similar to the “threshold immune modulation theory” [
23]. In addition, plasma mediator levels depend on several factors: the intensity of production, the number of cell receptors availability, the clearance of such mediators, the affinity of the receptors for such mediators. As an example, the interleukin (IL)-6 receptor is an agonist one, which differs from tumour necrosis factor (TNF)-soluble receptors and IL-1 receptors that are inhibitory; the consequence is that a low IL-6 level with a high level of receptor induces more cellular response than high level of IL-6 with a low level of receptors [
22]. This very important issue is showing that an IL-6 level alone may not be very predictive of the future response of the organism. DAMPs are also playing a key role and especially the endosomal DAMPs that are eliminated via the BPT and are capable of inducing cellular damage and apoptosis [
32]. This may explain the initial “positive” observational trials with HVHF. The reported improvement in hemodynamic status associated with or not with lactate reduction might mainly be the result of the fluid replacement therapy made with large volumes of crystalloids containing high buffer concentrations. As a consequence, the induced pH increase might have changed the affinity for catecholamines to their receptors improving hypotension [
28‐
30].